drugset / Trial / NCT03524235
Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL
Phase 1
Completed
20 enrolled
Noah Merin
Miltenyi Biomedicine GmbH · collabTeva Branded Pharmaceutical Products R&D, Inc. · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study seeks to examine the investigational use of the conditioning regimen (bendamustine, fludarabine, and rituximab) prior to haploidentical peripheral blood allogeneic stem cell transplantation with Post-Transplant Cyclophosphamide. The study will also test the investigational use of CD56-enriched Donor Lymphocyte Infusion to see if this treatment is safe, and whether or not it will help patients achieve better outcomes post-transplant, including reduced risk of Graft-Versus-Host Disease (GVHD), and preventing disease relapse.
Timeline
- Start
- 2018-07-18
- Primary completion
- 2021-11-07
- Completion
- 2024-11-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bendamustine | Small molecule | — | — |
| Subject | Fludarabine | Small molecule | — | — |
| Subject | Rituximab | Monoclonal antibody | — | — |